GlassScriptPhysician profile
Jason M Silversteen
NPI 1174783237
$202,194.91
in general payments reported to CMS, 2019-2025
18 companies · $2,278 in 2025
The $2,278 reported for 2025 was more than what 75% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $9,920 · 2021: $17K · 2022: $57K · 2023: $51K · 2024: $54K · 2025: $2,278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $98K · Food and Beverage: $4,147 · Consulting Fee: $3,700 · Honoraria: $600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $98,423.50 |
| Food and Beverage | $4,147.46 |
| Consulting Fee | $3,700.00 |
| Honoraria | $600.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $80,752.05 | 2020-2025 | Mavenclad, Mavenclad |
| Biogen, INC. | $51,287.98 | 2022-2025 | Tysabri, Tysabri, Vumerity |
| Genentech USA, INC. | $49,502.08 | 2019-2023 | Ocrevus |
| Amgen INC. | $12,150.00 | 2024 | Uplizna |
| Horizon Therapeutics Plc | $4,649.99 | 2021-2023 | Uplizna |
| Genentech, INC. | $3,469.54 | 2021-2025 | Ocrevus |
| Genzyme Corporation | $118.75 | 2019 | |
| Tg Therapeutics, INC. | $103.09 | 2025 | |
| Greenwich Biosciences, INC. | $29.48 | 2019 | |
| Csl Behring | $22.52 | 2019 | |
| Akcea Therapeutics, INC. | $22.32 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $18.41 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $17.41 | 2021 | |
| Ani Pharmaceuticals, INC. | $14.07 | 2022 | |
| Eisai INC. | $13.60 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $11.95 | 2019 | |
| Celgene Corporation | $11.67 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Silversteen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.